Real-world Evidence Supports Mogamulizumab’s Role in Treating CTCL

Mogamulizumab (Poteligeo, Kyowa Kirin International) performed well across real-world settings in patients with mycosis fungoides (MF) and Sézary Syndrome (SS).

Mogamulizumab (Poteligeo, Kyowa Kirin International) performed well across real-world settings in patients with mycosis fungoides (MF) and Sézary Syndrome (SS).